[Federal Register Volume 69, Number 161 (Friday, August 20, 2004)]
[Notices]
[Pages 51689-51690]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-19080]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2) notice

[[Page 51690]]

is hereby given of a meeting of the Recombinant DNA Advisory Committee 
(RAC), including a Safety Symposium on Recombinant DNA Research with 
Pathogenic Viruses.
    The Symposium entitled ``Safety Considerations in Recombinant DNA 
Research with Pathogenic Viruses'' will be held on September 21, 2004 
from 8 a.m. to 5 p.m. and September 22nd from 8 a.m. to 12 p.m. at the 
Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, Maryland 
20814.
    The RAC meeting will be held from 8 a.m. to 3 p.m. on September 23, 
2004 at the Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, 
Maryland 20814. The Committee will review human gene transfer protocol 
for use of an adeno-associated virus expressing the 293 bp human 
neuropeptide Y (NPY) open reading frame DNA under the transcriptional 
control of the CMV enhancer/chicken b-actin (CBA) hybrid promoter in 
subjects with intractable mesial temporal lobe epilepsy. The RAC 
meeting also includes the Data Management report and an update from the 
Clinical Trial Design Working Group.
    Contact Person: Stephen M. Rose, Ph.D., Executive Secretary, Office 
of Biotechnology Activities, National Institutes of Health, 6705 
Rockledge Drive, Room 750, Bethesda, MD 20892, (301) 496-9838. 
[email protected].
    Any interested person may file written comments with the committee 
by forwarding the statement to the Contact Person listed on this 
notice. The statement should include the name, address, telephone 
number and when applicable, the business or professional affiliation of 
the interested person.
    Information is also available on the Institute's/Center's home 
page: http://www4.od.nih.gov/oba/, where an agenda and any additional 
information for the meeting will be posted when available.

    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecules techniques could 
be used, it has been determined not too be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

    The meetings will be open to the public as indicated above, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed above in advance of the meeting.


(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.187, Undergraduate 
Scholarship Program for Individuals from Disadvantaged Backgrounds; 
93.22, Clinical Research Loan Repayment Program for Individuals from 
Disadvantaged Backgrounds; 93.232, Loan Repayment Program for 
Research Generally; 93.39, Academic Research Enhancement Award; 
93.936, NIH Acquired Immunodeficiency Syndrome Research Loan 
Repayment Program, National Institutes of Health, HHS)

    Dated: August 12, 2004.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 04-19080 Filed 8-19-04; 8:45 am]
BILLING CODE 4140-01-M